Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 5
Submit an article Journal homepage
47
Views
0
CrossRef citations to date
0
Altmetric
Review Articles

Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy

Kyaw Zin Theina Division of Hematology and Medical Oncology, Oregon Health and Science University/Knight Cancer Institute, Portland, Oregon, USAORCID Iconhttps://orcid.org/0000-0003-1518-1097
, MDORCID Icon,
Thura Win Htutb Department of Hematology, Aberdeen Royal Infirmary, University of Aberdeen, NHS Grampian, Scotland, UKORCID Iconhttps://orcid.org/0000-0002-5508-1472
, MBBSORCID Icon,
Yin Mon Myatc University College Dublin, Dublin, Ireland
, MBBS,
Myat Min Hand Department of Internal Medicine, Interfaith Medical Center, Brooklyn, New York, USA
, MD,
Myint Aung Wine Department of Internal Medicine, Lewis Gale Medical Center, Salem, Virginia, USA
, MD,
Ei Moe Phyuf Department of Hospital Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
, MD &
Thein Hlaing Oog Section of Benign Hematology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5201-731X
, MDORCID Icon show all
Pages 635-640 | Received 28 Feb 2023, Accepted 12 Jun 2023, Published online: 03 Jul 2023

  • Wendelboe AM, Raskbob GE. Global burden of thrombosis: epidemiological aspect. Circ Res. 2016;118(9):1340–1347. doi:10.1161/CIRCRESAHA.115.306841.
  • Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850. doi:10.1056/nejm200012213432504.
  • Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi:10.1007/s11239-015-1311-6.
  • Laporte S, Mismetti P, Décousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation. 2008;117(13):1711–1716. doi:10.1161/CIRCULATIONAHA.107.726232.
  • Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490–493. doi:10.1016/j.thromres.2009.12.023.
  • Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. doi:10.1002/cncr.23062.
  • Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81–91. doi:10.1007/s11239-015-1313-4.
  • Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(1):4902–4907. doi:10.1182/blood-2007-10-116327.
  • Tetzlaff ED, Cheng, JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008;2(6):267–272.
  • Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi:10.1200/jco.19.01461.
  • Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. doi:10.1016/s1470-2045(22)00160-7.
  • Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949. doi:10.1016/s1470-2045(09)70232-3.
  • Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane; 2019. https://training.cochrane.org/handbook.
  • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557–560. doi:10.1136/bmj.327.7414.557.
  • Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609. doi:10.1056/NEJMoa1108898.
  • Khorana AA, Soff G, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi:10.1056/NEJMoa1814630.
  • Mones JV, Streiff MB, Khorana AA, et al. Rivaroxaban prophylaxis for gastric/gastroesophageal junction tumors versus other tumors: a post-hoc analysis of the randomized CASSINI trial. Res Pract Thromb Haemost. 2021;5:e12549. doi:10.1002/rth2.12549.
  • Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to treat venous thromboembolism in patients with cancer. N Eng J Med. 2019;380(8):711–719. doi:10.1056/NEJMoa1814468.
  • Nayak AL, Zahrai A, Mallick R, et al. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: a post-hoc analysis of AVERT trial. Thromb Res. 2021;208:79–82. doi:10.1016/j.thromres.2021.10.018.
  • Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–1723. doi:10.1182/blood-2013-04-460121.
  • Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2016;27(3):270–274. doi:10.1097/mbc.0000000000000413.
  • Thein KZ, Yeung SJ, Oo TH. Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs). Asia Pac J Clin Oncol. 2018;14(3):210–216. doi:10.1111/ajco.12770.
  • Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009;20(1):1619–1630. doi:10.1093/annonc/mdp068.
  • Macbeth F, Noble S, Evans J, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34(5):488–494. doi:10.1200/jco.2015.64.0268.
  • Gezelius E, Bendahl PO, Gonçalves de Oliveira K, et al. Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN). Eur J Cancer. 2019;118:82–90. doi:10.1016/j.ejca.2019.06.015.
  • Ek L, Gezelius E, Bergman B, et al. Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018;29(2):398–404. doi:10.1093/annonc/mdx716.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.